Achillion Pharmaceuticals

For Patients

Achillion Pharmaceuticals, Inc. is a science-driven, patient-focused company. Our mission is to discover and advance potentially life-saving medicines for patients with rare diseases, such as C3G and PNH. We are committed to delivering on the promise of complement-based therapeutics, including our portfolio of factor D inhibitor compounds, as well as educating and supporting patients and their caregivers. Learn more about Achillion.

C3 GLOMERULOPATHY (C3G)

For information on Achillion’s C3G clinical trials, please visit:

  • Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN): NCT03459443
  • Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G): NCT03369236
  • Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN: NCT03124368

WeC3G Patient Support Initiative

  • Unites voices of community impacted by disease
  • Connects patients and caregivers to each other and to information, support and resources that can shine the light on C3G
  • Raises awareness and understanding

Visit site

Natural History Study

  • Ongoing study conducted by Imperial College of London in up to 400 patients globally
  • Retrospective and prospective data collection to track natural course of disease over 4 years

Visit site

C3G Patient-Focused Drug Development

  • First PFDD meeting focused on a renal disease led by the NKF and FDA
  • Sponsored by Achillion with a goal of understanding the C3G patient and caregiver experience and perspective

Visit site

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

For additional information on Achillion’s PNH clinical trials, please visit:

  • A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab (PNH): NCT03472885
  • A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)): NCT03053102
  • A Long-term Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): NCT03181633